• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Astellas Pharma hires global executive Eric Terhaerdt

Astellas Pharma hires global executive Eric Terhaerdt

January 16, 2015
CenterWatch Staff

Eric Terhaerdt has been named senior vice president of Global Development Operations for Astellas Pharma, based in Tokyo, Japan. Terhaerdt will be located at Astellas' headquarters for the Americas in Northbrook, Ill., and will report to Dr. Bernie Zeiher, executive vice president, Global Development and Therapeutic Area head: immunology, infectious disease, transplantation and central nervous system and pain, with Astellas Pharma Global Development.

Terhaerdt will be responsible for establishing the global direction of the drug development operations of Astellas in the Netherlands and the U.S. and will work closely with Japan Development Operations to ensure global operational effectiveness and efficiency. As a key direct report to the executive vice president of Global Development, he will play an instrumental role in defining development strategy and ensuring the effective and efficient development of the Astellas product portfolio.

Terhaerdt spent over 20 years with AstraZeneca, working in a variety of global leadership roles with increasing responsibility in the areas of clinical research, clinical development, clinical quality, strategy and performance and scientific and technical evaluations.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing